These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22749185)

  • 1. Imaging of VMAT2 binding sites in the brain by (18)F-AV-133: the effect of a pseudo-carrier.
    Zhu L; Qiao H; Lieberman BP; Wu J; Liu Y; Pan Z; Ploessl K; Choi SR; Chan P; Kung HF
    Nucl Med Biol; 2012 Oct; 39(7):897-904. PubMed ID: 22749185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain uptake of a non-radioactive pseudo-carrier and its effect on the biodistribution of [(18)F]AV-133 in mouse brain.
    Wu X; Zhou X; Zhang S; Zhang Y; Deng A; Han J; Zhu L; Kung HF; Qiao J
    Nucl Med Biol; 2015 Jul; 42(7):630-6. PubMed ID: 25910857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2.
    Zhu L; Liu Y; Plössl K; Lieberman B; Liu J; Kung HF
    Nucl Med Biol; 2010 Feb; 37(2):133-41. PubMed ID: 20152712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VMAT2 imaging agent, D6-[
    Zhao R; Zha Z; Yao X; Ploessl K; Choi SR; Liu F; Zhu L; Kung HF
    Nucl Med Biol; 2019; 72-73():26-35. PubMed ID: 31330409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deuterated
    Liu F; Choi SR; Zha Z; Ploessl K; Zhu L; Kung HF
    Nucl Med Biol; 2018 Feb; 57():42-49. PubMed ID: 29306111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding characteristics of 9-fluoropropyl-(+)-dihydrotetrabenzazine (AV-133) to the vesicular monoamine transporter type 2 in rats.
    Tsao HH; Lin KJ; Juang JH; Skovronsky DM; Yen TC; Wey SP; Kung MP
    Nucl Med Biol; 2010 May; 37(4):413-9. PubMed ID: 20447551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.
    Chao KT; Tsao HH; Weng YH; Hsiao IT; Hsieh CJ; Wey SP; Yen TC; Kung MP; Lin KJ
    Synapse; 2012 Sep; 66(9):823-31. PubMed ID: 22623146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo studies of the SERT-selective [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease.
    Wang JL; Oya S; Parhi AK; Lieberman BP; Ploessl K; Hou C; Kung HF
    Nucl Med Biol; 2010 May; 37(4):479-86. PubMed ID: 20447560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.
    Goswami R; Ponde DE; Kung MP; Hou C; Kilbourn MR; Kung HF
    Nucl Med Biol; 2006 Aug; 33(6):685-94. PubMed ID: 16934687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133.
    Okamura N; Villemagne VL; Drago J; Pejoska S; Dhamija RK; Mulligan RS; Ellis JR; Ackermann U; O'Keefe G; Jones G; Kung HF; Pontecorvo MJ; Skovronsky D; Rowe CC
    J Nucl Med; 2010 Feb; 51(2):223-8. PubMed ID: 20080893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters.
    Kung MP; Hou C; Goswami R; Ponde DE; Kilbourn MR; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):239-46. PubMed ID: 17383573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [
    Weng CC; Huang SL; Chen ZA; Lin KJ; Hsiao IT; Yen TC; Kung MP; Wey SP; Hsu CH
    Ann Nucl Med; 2017 Aug; 31(7):506-513. PubMed ID: 28451991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sigma receptor binding of tetrabenazine series tracers targeting VMAT2 in rat pancreas.
    Tsao HH; Skovronsky DM; Lin KJ; Yen TC; Wey SP; Kung MP
    Nucl Med Biol; 2011 Oct; 38(7):1029-34. PubMed ID: 21982574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Efficient Automated Radiosynthesis and Bioactivity Confirmation of VMAT2 Tracer [
    Zhao C; Liu C; Tang J; Xu Y; Xie M; Chen Z
    Mol Imaging Biol; 2020 Apr; 22(2):265-273. PubMed ID: 31165386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of anesthetics on vesicular monoamine transporter type 2 binding to ¹⁸F-FP-(+)-DTBZ: a biodistribution study in rat brain.
    Chen Z; Tang J; Liu C; Li X; Huang H; Xu X; Yu H
    Nucl Med Biol; 2016 Jan; 43(1):124-129. PubMed ID: 26526872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body biodistribution and radiation dosimetry of 18F-FP-(+)-DTBZ (18F-AV-133): a novel vesicular monoamine transporter 2 imaging agent.
    Lin KJ; Weng YH; Wey SP; Hsiao IT; Lu CS; Skovronsky D; Chang HP; Kung MP; Yen TC
    J Nucl Med; 2010 Sep; 51(9):1480-5. PubMed ID: 20720042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [¹⁸F]FP-DTBZ in baboons.
    Harris PE; Farwell MD; Ichise M
    Nucl Med Biol; 2013 Jan; 40(1):60-4. PubMed ID: 23102539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of [(18)F]fluoroalkyl derivatives of dihydrotetrabenazine in rat and monkey brain.
    Kilbourn MR; Hockley B; Lee L; Hou C; Goswami R; Ponde DE; Kung MP; Kung HF
    Nucl Med Biol; 2007 Apr; 34(3):233-7. PubMed ID: 17383572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
    Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
    Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.
    Gao R; Zhang G; Chen X; Yang A; Smith G; Wong DF; Zhou Y
    PLoS One; 2016; 11(10):e0164762. PubMed ID: 27764160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.